Trial Profile

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Pexastimogene devacirepvec (Primary) ; Tremelimumab (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions

Most Recent Events

26 Sep 2023 Status changed from active, no longer recruiting to completed.
13 Jan 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2023.
25 Oct 2020 Results presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com